首页>
外国专利>
BIOMARKERS FOR ANTIBODY-DRUG CONJUGATE MONOTHERAPY OR COMBINATION THERAPY
BIOMARKERS FOR ANTIBODY-DRUG CONJUGATE MONOTHERAPY OR COMBINATION THERAPY
展开▼
机译:用于抗体 - 药物共轭物单疗法或联合治疗的生物标志物
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to biomarkers of use in cancer therapy, wherein the therapy comprises treatment with anti-Trop-2, anti-CEACAM5 or anti-HLA-DR ADCs (antibody-drug conjugates), alone or in combination with and one or more anti-cancer agents, such as a DDR inhibitor, an ABCG2 inhibitor, a microtubule inhibitor, a checkpoint inhibitor, a PI3K inhibitor, an AKT inhibitor, a CDK 4 inhibitor, a CDK 5 inhibior, a tyrosine kinase inhibitor or a platinum-based chemotherapeutic agent. Preferably, the combination therapy has a synergistic effect on inhibiting tumor growth. The biomarkers are of use to predict efficacy and/or toxicity of ADC therapy, determine tumor response to treatment, identify minimal residual disease or relapse, determine prognosis, stratify patients for initial therapy or to optimize treatment for the patient, based on the specific biomarkers detected.
展开▼